U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H28F2O4
Molecular Weight 394.4521
Optical Activity UNSPECIFIED
Defined Stereocenters 9 / 9
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DIFLUCORTOLONE

SMILES

[H][C@@]12C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]3(F)[C@@]2([H])C[C@H](F)C4=CC(=O)C=C[C@]34C

InChI

InChIKey=OGPWIDANBSLJPC-RFPWEZLHSA-N
InChI=1S/C22H28F2O4/c1-11-6-13-14-8-16(23)15-7-12(26)4-5-21(15,3)22(14,24)18(28)9-20(13,2)19(11)17(27)10-25/h4-5,7,11,13-14,16,18-19,25,28H,6,8-10H2,1-3H3/t11-,13+,14+,16+,18+,19-,20+,21+,22+/m1/s1

HIDE SMILES / InChI

Molecular Formula C22H28F2O4
Molecular Weight 394.4521
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 9 / 9
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including, www.ncbi.nlm.nih.gov/pubmed/23213332

Diflucortolone (used in the form of valerate prodrug) is a corticosteroid developed for the treatment of inflammatory skin diseases. It is supposed that Diflucortolone acts by inducing Annexin A1, a phospholipase A2 inhibitory protein, and thus controls the biosynthesis of prostagladins and leukotrienes. The drug is marketed as a cream under the tradename Nerisone.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P04083
Gene ID: 301.0
Gene Symbol: ANXA1
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
NERISONE

Approved Use

NERISONE® (diflucortolone valerate) preparations are indicated for the topical treatment of corticosteroid-responsive acute and chronic skin diseases, where anti-inflammatory, anti-allergic and anti-pruritic action is required for a maximum duration of 4 weeks.
PubMed

PubMed

TitleDatePubMed
[Clinical comparative study of between difluocortolone and flumethasone].
1977
[Clinical trial of diflucortolone. Preliminary report].
1981
Local anti-inflammatory activity and systemic side effects of NM-135, a new prodrug glucocorticoid, in an experimental inflammatory rat model.
1998 Dec
Congenital infantile digital fibromatosis: a case report and review of the literature.
2009 Dec 28
Patents

Sample Use Guides

Apply a thin layer and gently rub in using only enough to cover the affected area once or twice a day for a maximum of 4 weeks.
Route of Administration: Topical
In the vasoconstriction test on human skin, in which hyperemia has been experimentally induced, a water/oil emulsion with 0.001% diflucortolone valerate is as effective as a similar preparation containing 0.1% fluocortolone.
Substance Class Chemical
Created
by admin
on Sat Dec 16 16:16:08 UTC 2023
Edited
by admin
on Sat Dec 16 16:16:08 UTC 2023
Record UNII
K253365DXI
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DIFLUCORTOLONE
INN   MART.   MI   USAN   WHO-DD  
USAN   INN  
Official Name English
PREGNA-1,4-DIENE-3,20-DIONE, 6,9-DIFLUORO-11,21-DIHYDROXY-16-METHYL-, (6.ALPHA.,11.BETA.,16.ALPHA.)-
Systematic Name English
DIFLUCORTOLONE [USAN]
Common Name English
DIFLUCORTOLONE [MART.]
Common Name English
6α,9-Difluoro-11β,21-dihydroxy-16α-methylpregna-1,4-diene-3,20-dione
Systematic Name English
diflucortolone [INN]
Common Name English
Diflucortolone [WHO-DD]
Common Name English
DIFLUCORTOLONE [MI]
Common Name English
Classification Tree Code System Code
WHO-VATC QD07XC04
Created by admin on Sat Dec 16 16:16:08 UTC 2023 , Edited by admin on Sat Dec 16 16:16:08 UTC 2023
WHO-ATC D07AC06
Created by admin on Sat Dec 16 16:16:08 UTC 2023 , Edited by admin on Sat Dec 16 16:16:08 UTC 2023
WHO-ATC D07BC04
Created by admin on Sat Dec 16 16:16:08 UTC 2023 , Edited by admin on Sat Dec 16 16:16:08 UTC 2023
WHO-VATC QD07AC06
Created by admin on Sat Dec 16 16:16:08 UTC 2023 , Edited by admin on Sat Dec 16 16:16:08 UTC 2023
WHO-ATC D07XC04
Created by admin on Sat Dec 16 16:16:08 UTC 2023 , Edited by admin on Sat Dec 16 16:16:08 UTC 2023
WHO-VATC QD07BC04
Created by admin on Sat Dec 16 16:16:08 UTC 2023 , Edited by admin on Sat Dec 16 16:16:08 UTC 2023
NCI_THESAURUS C521
Created by admin on Sat Dec 16 16:16:08 UTC 2023 , Edited by admin on Sat Dec 16 16:16:08 UTC 2023
Code System Code Type Description
EPA CompTox
DTXSID50180705
Created by admin on Sat Dec 16 16:16:08 UTC 2023 , Edited by admin on Sat Dec 16 16:16:08 UTC 2023
PRIMARY
WIKIPEDIA
Diflucortolone
Created by admin on Sat Dec 16 16:16:08 UTC 2023 , Edited by admin on Sat Dec 16 16:16:08 UTC 2023
PRIMARY
EVMPD
SUB07128MIG
Created by admin on Sat Dec 16 16:16:08 UTC 2023 , Edited by admin on Sat Dec 16 16:16:08 UTC 2023
PRIMARY
MESH
D004060
Created by admin on Sat Dec 16 16:16:08 UTC 2023 , Edited by admin on Sat Dec 16 16:16:08 UTC 2023
PRIMARY
MERCK INDEX
m4432
Created by admin on Sat Dec 16 16:16:08 UTC 2023 , Edited by admin on Sat Dec 16 16:16:08 UTC 2023
PRIMARY Merck Index
ChEMBL
CHEMBL509924
Created by admin on Sat Dec 16 16:16:08 UTC 2023 , Edited by admin on Sat Dec 16 16:16:08 UTC 2023
PRIMARY
PUBCHEM
11954369
Created by admin on Sat Dec 16 16:16:08 UTC 2023 , Edited by admin on Sat Dec 16 16:16:08 UTC 2023
PRIMARY
ECHA (EC/EINECS)
220-022-6
Created by admin on Sat Dec 16 16:16:08 UTC 2023 , Edited by admin on Sat Dec 16 16:16:08 UTC 2023
PRIMARY
INN
2395
Created by admin on Sat Dec 16 16:16:08 UTC 2023 , Edited by admin on Sat Dec 16 16:16:08 UTC 2023
PRIMARY
FDA UNII
K253365DXI
Created by admin on Sat Dec 16 16:16:08 UTC 2023 , Edited by admin on Sat Dec 16 16:16:08 UTC 2023
PRIMARY
DRUG CENTRAL
3141
Created by admin on Sat Dec 16 16:16:08 UTC 2023 , Edited by admin on Sat Dec 16 16:16:08 UTC 2023
PRIMARY
NCI_THESAURUS
C87231
Created by admin on Sat Dec 16 16:16:08 UTC 2023 , Edited by admin on Sat Dec 16 16:16:08 UTC 2023
PRIMARY
SMS_ID
100000083157
Created by admin on Sat Dec 16 16:16:08 UTC 2023 , Edited by admin on Sat Dec 16 16:16:08 UTC 2023
PRIMARY
DRUG BANK
DB09095
Created by admin on Sat Dec 16 16:16:08 UTC 2023 , Edited by admin on Sat Dec 16 16:16:08 UTC 2023
PRIMARY
RXCUI
3392
Created by admin on Sat Dec 16 16:16:08 UTC 2023 , Edited by admin on Sat Dec 16 16:16:08 UTC 2023
PRIMARY RxNorm
CAS
2607-06-9
Created by admin on Sat Dec 16 16:16:08 UTC 2023 , Edited by admin on Sat Dec 16 16:16:08 UTC 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY